Embecta Aktie

Embecta reported adjusted EPS of $0.56 and revenue of $271.7 million for Q3 2026, significantly beating consensus estimates. The company raised its forecasts for adjusted operating margin to 23.5–24% and adjusted EPS to $1.80–1.90, but left its 2026 revenue guidance unchanged. Despite a year‑over‑year revenue decline, Embecta benefited from cost cuts, the contribution from the acquisition of Owen Mumford and a sequential improvement in results; however, the U.S. business remains under pressure. » Plus sur de.investing.com

Embecta cut its U.S. guidance after a challenging quarter marked by loss of shelf position at a major retailer—attributed mainly to price pressure—softer insulin pen prescriptions and inventory adjustments. CEO Devdatt Kurdikar said the company is assessing whether the weakness is temporary or structural amid rising GLP-1 affordability and insurance changes. Embecta is accelerating diversification via lower‑priced pen needles and syringes, a GLP‑1 B2B channel and the pending Owen Mumford acquisition while targeting about $100 million in free cash flow and prioritizing debt reduction and buybacks. » Plus sur finance.yahoo.com

S&P Global Ratings cut Embecta’s rating from B+ to B with a stable outlook after second fiscal quarter sales fell 14%. Reasons cited include roughly 20% currency‑adjusted revenue weakness in insulin pen needles, market share losses to a lower‑priced competitor, and weaker US market demand (lower insulin usage, a shift to cheaper channels, increased use of automated systems and GLP‑1 drugs). S&P expects about a 6% sales decline in 2026, an adjusted margin down roughly 800 basis points to 29%, and leverage of 4.5–5x; the acquisition of Owen Mumford is expected to be financed via the revolving credit facility and the dividend will be cut to reduce debt. » Plus sur de.investing.com